bioAffinity regains Nasdaq compliance; stock continues trading on Capital Market

bioAffinity Technologies, Inc.

Received Nasdaq letter Oct 14 confirming compliance with minimum bid price ($1.00) and stockholders' equity ($2.5M) rules.
Subject to one-year Mandatory Panel Monitor; if equity rule breached, no additional time to regain compliance but hearing available.
Common stock (BIAF) and warrants (BIAFW) continue trading on Nasdaq Capital Market.
CEO Maria Zannes: regaining compliance allows focus on CyPath Lung test and building shareholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.